Arthritis Study Propels Pfizer Into $12 Billion Market
November 8, 2010
Pfizer Inc.’s experimental pill for rheumatoid arthritis reduced pain and inflammation for 71 percent of patients in a study that may help the company with $12 billion in yearly sales, according to Bloomberg. Pfizer is racing three biotechnology companies to sell the first pill in a decade for rheumatoid arthritis, which destroys joints in 1.3 million Americans. Pfizer’s most recent finding, in the last of three phrases of research usually needed for U.S. marketing approval, will be reported Nov. 10 at the American College of Rheumatology meeting in Atlanta. Revenue from tasocitinib may help offset Pfizer losses when its top-selling Lipitor cholesterol pill, with $11.4 billion in annual sales, faces competition next year from cheaper copies in the U.S. The rheumatoid arthritis market is dominated by three injectable drugs known as anti-TNF treatments, which cost as much as $20,000 a year and leave patients susceptible to infections.